Bedrijfsoverzicht
Genprex, Inc. is a clinical-stage gene therapy company dedicated to the development of novel therapeutic interventions designed to administer disease-fighting genes to target specific patient populations suffering from cancer and diabetes. Operating within the healthcare sector and specifically the biotechnology industry, the company focuses on translating genetic research into viable clinical treatments that aim to address critical unmet medical needs in oncology and endocrinology. The enterprise maintains a modest operational scale with a reported market capitalization of $10.40 million and employs a workforce of 13 individuals to execute its research and development pipeline. The current market capitalization of $10.40 million, combined with the absence of reported annual revenue figures, indicates that the company is in an early-stage development phase where value is primarily derived from intellectual property and clinical progress rather than commercial sales. This limited employee count and lack of revenue generation reflect the typical characteristics of a clinical-stage biotechnology firm that has not yet achieved commercial product launches.
Financiële gezondheid
The company reported no revenue over the trailing twelve-month period, resulting in a net income of $-16,228,953 and an EBITDA of $-15,508,926, which reveals a cost structure dominated by research and development expenditures rather than operational overhead or cost of goods sold. With a free cash flow of $-10,226,542, the company is currently consuming cash reserves to fund its clinical trials and development activities, indicating a lack of financial flexibility until successful commercialization occurs. The gross margin, operating margin, and profit margin are all recorded at 0.0%, a standard metric for pre-revenue clinical-stage entities where revenue does not yet exist to calculate profitability percentages. Despite the negative net income, the balance sheet retains $7.83 million in cash while holding zero debt, suggesting a conservative capital structure that avoids leverage despite significant operating losses. The debt-to-equity ratio is effectively N/A due to the absence of debt and the specific financial context of the company. The current ratio stands at 3.84, which indicates a strong short-term liquidity position relative to current liabilities, providing a substantial buffer to sustain operations over the short term. Furthermore, the return on equity is -338.7% and the return on assets is -135.8%, metrics that reveal the management team is currently deploying capital in a way that generates significant losses per unit of equity and assets, consistent with high-burn biotechnology development models.
Waarderingsbeoordeling
The trailing twelve-month P/E ratio is N/A because there is no positive earnings, while the forward P/E is listed at -0.53, implying that the market anticipates continued negative earnings or a specific accounting treatment for future periods rather than a traditional multiple expansion. The price-to-book ratio is 0.30, indicating that the company's market capitalization is significantly below its book value, which often occurs in biotechnology firms where tangible assets are minimal compared to the value of their intellectual property pipeline. The price-to-sales ratio is N/A due to the lack of revenue, and the EV/EBITDA stands at -0.17, suggesting a valuation framework that relies heavily on discounted cash flow models rather than traditional earnings multiples. The stock's 52-week trading range spans from a low of $1.15 to a high of $55.00, meaning the current price sits at a significant discount to the recent high and reflects the high volatility typical of small-cap biotechnology securities. The beta value of -0.67 indicates a negative correlation with the broader market, suggesting that the stock price tends to move inversely to the general market index, which presents a unique risk profile distinct from standard equities.
Growth & Income
The revenue growth year-over-year and earnings growth year-over-year are both N/A, as the company has not yet generated revenue to calculate a growth rate, implying that the traditional growth metrics used for mature companies are not yet applicable to this clinical-stage entity. Since the company does not pay dividends, the dividend yield is N/A and the payout ratio is 0.0%, confirming that the organization reinvests all available cash flow and raises capital primarily to fund its ongoing research and development initiatives rather than distributing income to shareholders. The overall growth and income profile is characterized by a complete absence of current commercial earnings, with the company's primary objective being the advancement of its gene therapy programs for cancer and diabetes patients rather than immediate shareholder returns.